Current perspective: Osimertinib-induced QT prolongation: new drugs with new side-effects need careful patient monitoring
European Journal of Cancer2018Vol. 91, pp. 92–98
Citations Over TimeTop 10% of 2018 papers
Related Papers
- → Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib(2017)60 cited
- → ALKrearrangements as mechanisms of acquired resistance to osimertinib inEGFRmutant non‐small cell lung cancer(2021)23 cited
- → A Case Report of Successful Treatment With Crizotinib to Overcome Resistance to Osimertinib in an EGFR Mutated Non–Small-Cell Lung Cancer Patient Harboring an Acquired MET Exon 14 Mutation(2021)10 cited
- → TPD52L1-ROS1 Rearrangement as a New Acquired Resistance Mechanism to Osimertinib That Responds to Crizotinib in Combination With Osimertinib in Lung Adenocarcinoma(2020)9 cited
- → Personalized Medicine in Woman Lung Cancer: Crizotinib and Osimertinib Association to Overcome Osimertinib Resistance(2020)